Identifying and developing products that will improve the health and quality of life of patients remains a primary focus of Forest Laboratories.
01.17.2012 - Forest Laboratories, Inc. Reports Fiscal Year Third Quarter 2012 Earnings Per Share of $1.04
01.03.2012 - Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2012 Third Quarter Earnings
10.27.2011 - Ironwood and Forest to Present Linaclotide Results from Phase 2B and Phase 3 Trials in Patients with Irritable Bowel Syndrome with Constipation or Chronic Constipation
10.24.2011 - Ironwood and Forest Announce Linaclotide New Drug Application for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Constipation Accepted for FDA Review